Analogic Announces Financial Results for the Second Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Analogic Announces Financial Results for the Second Quarter Ended January 31, 2015 and Declares Quarterly Cash Dividend

PEABODY, Mass., March 10, 2015 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq: ALOG ), enabling the world's medical imaging and aviation security technology, today announced results for its second quarter ended January 31, 2015.

Highlights during the second quarter (comparisons are against Q2 of fiscal 2014) included:

  • Revenue of $134 million, down 5%
  • Gross margin of 43%
  • GAAP operating margin of 9%; Non-GAAP operating margin of 13%
  • GAAP diluted EPS of $0.78; Non-GAAP diluted EPS of $1.08

Revenue for the second quarter of fiscal 2015 was $133.9 million, a decrease of 5% compared with revenue of $141.4 million in the second quarter of fiscal 2014. GAAP net income for the second quarter of fiscal 2015 was $9.8 million, or $0.78 per diluted share, compared with net income of $19.3 million, or $1.53 per diluted share, in the second quarter of fiscal 2014. Included in our GAAP net income for the second quarter of fiscal 2014 were non-recurring tax benefits of $8.8 million, or $0.69 per diluted share, primarily associated with our Canadian operations.

Non-GAAP net income for the second quarter was $13.6 million, or $1.08 per diluted share, compared with $14.8 million, or $1.17 per diluted share, in the prior year's second quarter. Our non-GAAP results do not include the tax benefit noted above. A reconciliation of GAAP to non-GAAP results is included as an attachment to this press release.

For the first six months of fiscal 2015, revenue totaled $252.3 million, consistent with the same period in the prior year. Year-to-date GAAP net income was $13.5 million, or $1.07 per diluted share, compared with $15.5 million, or $1.23 per diluted share, from the same period last year. Included in our GAAP net income last fiscal year were the nonrecurring tax benefits noted above of $8.8 million, or $0.69 per diluted share. Year-to-date non-GAAP net income was $21.5 million, or $1.70 per diluted share, compared with $15.6 million, or $1.23 per diluted share, in the same period last year. Our non-GAAP results do not include the tax benefit noted above.

Jim Green, president and CEO, commented, "Our performance during the first half of the year was in-line with our expectations, with strong revenue growth expected in the second half of the fiscal year. Our Ultrasound business continued to see double-digit growth on a constant currency basis. We also continued to build our backlog in Security and Detection, putting us in a position for strong double-digit revenue growth in this segment this fiscal year."

Green continued, "We are maintaining our fiscal 2015 outlook of revenue growing mid-single digits with a 1-2 point improvement in non-GAAP operating margin."

Segment Revenues

Revenue from our Medical Imaging segment was $73.1 million for the second quarter of fiscal 2015, down 8% from revenue of $79.6 million in the same period of fiscal 2014. The decline in Medical Imaging revenues was primarily driven by the timing of shipments compared to the prior year. On a year-to-date basis, Medical Imaging revenue was $139.9 million, consistent with the prior year.

Our Ultrasound segment revenue was $42.5 million for the second quarter of fiscal 2015, 6% growth over the $40.1 million in the same period of fiscal 2014. On a constant currency basis, the growth in Ultrasound was 10% for the quarter. Ultrasound revenue growth was driven by direct sales in North America and in China, as well as higher sales of OEM ultrasound probes. Year-to-date, Ultrasound revenue was $80.3 million, up 7% from the prior year, or 10% in constant currency.

Security and Detection segment revenue was $18.3 million for the second quarter of fiscal 2015, down 16% from revenue of $21.7 million in the same period of fiscal 2014, due to timing of shipments as the majority of the growing backlog is scheduled to ship in the second half of this fiscal year. Year to date, Security and Detection revenue was $32.1 million, down 13% from the prior year.

Quarterly Cash Dividend

On March 5, 2015, Analogic's Board of Directors declared a $0.10 cash dividend for each common share for its second fiscal quarter ended January 31, 2015. The cash dividend will be payable on April 3, 2015 to shareholders of record on March 20, 2015.

Use of Non-GAAP Financial Measures

This document includes non-GAAP financial measures that are not in accordance with, nor an alternative to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.

Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results. An explanation and a reconciliation of our non-GAAP measures are provided at the end of this press release.

Forward-Looking Statements

Any statements about future expectations, plans, and prospects for the Company, including statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to product development and commercialization, limited demand for the Company's products, limited number of customers, risks associated with competition, uncertainties associated with regulatory agency approvals, competitive pricing pressures, downturns in the economy, the risk of potential intellectual property litigation, acquisition related risks, and other factors discussed in our most recent quarterly and annual reports filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date of this document. While the Company anticipates that subsequent events and developments will cause the Company's views to change, the Company specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any later date.

Conference Call

Analogic will conduct an investor conference call on Tuesday, March 10, 2015 at 5:00 p.m. (ET) to discuss results for the second quarter ended January 31, 2015. To participate in the conference call, dial 1-866-823-6992, or 1-334-323-7225 for international callers, approximately ten minutes before the conference is scheduled to begin. Inform the operator that you wish to join the Analogic conference call, passcode 42748. You will then be asked for your name, organization, and telephone number, and be connected to the conference. The earnings release and, just prior to the call, presentation materials related to the quarterly financial information will be posted on the Company's investor relations website at http://investor.analogic.com .

The call will also be available via webcast in listen-only mode. To listen to the webcast, visit http://investor.analogic.com approximately five to ten minutes before the conference is scheduled to begin. A telephone digital replay will be available approximately two hours after the call is completed through midnight (ET), Friday, April 10, 2015. To access the digital replay, dial 1-877-919-4059, or 1-334-323-0140 for international callers. The passcode is 53618958.         

The replay of the conference call webcast will be archived at http://investor.analogic.com approximately three hours after the call is completed and will be available through midnight (ET), Friday, April 10, 2015.

About Analogic

Analogic (Nasdaq: ALOG ) provides leading-edge healthcare and security technology solutions to advance the practice of medicine and save lives. We are recognized around the world for advanced imaging and real-time guidance technologies used for disease diagnosis and treatment as well as for automated threat detection. Our market-leading ultrasound systems, led by our flagship BK Ultrasound brand, used in procedure-driven markets such as urology, surgery, and point-of-care, are sold to clinical practitioners around the world. Our advanced imaging technologies are also used in computed tomography (CT), magnetic resonance imaging (MRI), and digital mammography systems, as well as automated threat detection systems for aviation security. Analogic is headquartered just north of Boston, Massachusetts. For more information, visit www.analogic.com .

Analogic and the globe logo are registered trademarks of Analogic Corporation.

 

CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
               
  Three Months Ended   Six Months Ended
(In thousands, except per share data) January 31, 2015   January 31, 2014   January 31, 2015   January 31, 2014
               
Net revenue:              
Product  $131,272    $139,471    $248,207    $247,925
Engineering  2,673   1,966    4,054    3,594
Total net revenue  133,945   141,437    252,261    251,519
Cost of sales:              
Product  74,077    78,767    139,215    144,393
Engineering  2,375   1,586    3,554    3,106
Total cost of sales  76,452   80,353    142,769   147,499
               
Gross profit  57,493   61,084    109,492    104,020
Operating expenses:              
Research and product development  16,425    20,026    33,794    38,880
Selling and marketing  15,846    14,695    31,355    29,265
General and administrative 13,073   12,944   27,295    27,860
Restructuring  (152)    335    (210)    296
Total operating expenses  45,192   48,000    92,234    96,301
               
Income from operations  12,301   13,084    17,258    7,719
Total other expense, net  (169)    (357)    (51)    (778)
Income before income taxes  12,132    12,727    17,207    6,941
Provision for (benefit from) income taxes  2,302   (6,587)    3,723    (8,598)
Net income  $9,830    $19,314    $13,484    $15,539
               
Net income per share              
Basic  $0.79    $1.56    $1.09    $1.25
Diluted  $0.78    $1.53    $1.07    $1.23
               
Dividends declared and paid per share  $0.10    $0.10    $0.20    $0.20
               
Weighted-average shares outstanding:              
Basic  12,378    12,417    12,393    12,430
Diluted  12,558    12,656    12,588    12,684

 

CONDENSED CONSOLIDATED BALANCE SHEETS  
(Unaudited)  
         
     
(In thousands)        
     
Assets:   January 31, 2015   July 31, 2014
Cash and cash equivalents    $116,163    $114,540
Accounts receivable, net    94,577    106,436
Inventory    134,798    124,777
Other current assets    27,306    28,021
Total current assets    372,844    373,774
Property, plant, and equipment, net    108,812    114,165
Intangible assets and goodwill, net    111,335    114,321
Other non-current assets    10,461    12,082
Total Assets    $603,452    $614,342
         
Liabilities and Stockholders' Equity:        
Accounts payable    $30,336    $37,241
Accrued liabilities    31,486    33,465
Other current liabilities    12,137    13,807
Total current liabilities    73,959    84,513
Long-term liabilities    16,919    17,249
Stockholders' equity    512,574    512,580
Total Liabilities and Stockholders' Equity    $603,452    $614,342

UNAUDITED SUPPLEMENTAL INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP MEASURES

We provide non-GAAP income from operations, other income, net income, and diluted net income per share as supplemental measures to reported results regarding our operational performance. These financial measures exclude the impact of certain items and, therefore, have not been calculated in accordance with GAAP. The adjustments to these financial measures, and the basis for such adjustments, are outlined below:

Share-Based Compensation Expense

We incur expense related to share-based compensation included in the reported presentation of cost of sales, research and development, selling and marketing, and general and administrative expense. Although share-based compensation is an expense and viewed as a form of compensation, these expenses vary in amount from period to period. In addition, fluctuations in market price and volatility of our shares, risk-free interest rates, the expected term and forfeiture rates of the awards impact the expense period to period. A portion of our equity compensation is performance-based, which drives volatility in expense as estimated performance-based metrics are updated for actual and forecasted results. Our management team believes that exclusion of these expenses allows comparisons of operating results that are consistent between periods and allows comparisons of our operating results to those of other companies that disclose non-GAAP financial measures that exclude share-based compensation.

BK Medical Distributor Matter Inquiry-Related Costs

In fiscal year 2011, we identified transactions involving our Danish subsidiary, BK Medical, and certain of its foreign distributors, with respect to which we have raised questions concerning compliance with law and our business policies. We have concluded that the identified transactions have been properly accounted for in our reported consolidated financial statements in all material respects. During the three and six months ended January 31, 2015 we incurred $0.4 million and $1.1 million of pre-tax inquiry-related costs, respectively. We incurred $0.6 million and $0.9 million of pre-tax inquiry-related costs during the three and six months ended January 31, 2014, respectively.

Acquisition-related Expenses

Acquisition-related expenses relate to the amortization of intangibles and fair value adjustments associated with assets acquired and contingent liabilities from our business combinations. These expenses also include other transaction costs related to the acquisitions. The intangible assets are valued at the time of acquisition and are amortized over their estimated economic life. We believe the exclusion of these acquisition-related expenses allow comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses. During the three and six months ended January 31, 2015, we incurred $2.3 million and $4.5 million of pre-tax acquisition-related expenses, respectively. We incurred $2.0 million and $4.5 million of pre-tax acquisition-related costs during the three and six months ended January 31, 2014, respectively.

Restructuring Charges

During the fourth quarter of fiscal year 2014, we implemented our fiscal year 2014 restructuring plan (FY14 restructuring plan) to optimize our operations in Peabody, Massachusetts, which affected 48 employees. In May 2013, we announced our fiscal year 2013 restructuring plan (FY13 restructuring plan) primarily relating to severance and personnel related costs of 115 involuntarily terminated employees, as well as for facility exit costs associated with restructuring activities, including the consolidation of manufacturing and certain support activities currently conducted at the Ultrasonix facility in Vancouver, into operations at our existing facilities, closure of the Ultrasonix sales subsidiary in Paris, France, the transition costs associated with the planned closure of our Englewood, Colorado facility, as we consolidated certain ultrasound transducer manufacturing and development activities into our State College, Pennsylvania facility, and optimization of our operations in Montreal, Canada and Peabody Massachusetts. We continue to have adjustments on our FY14 restructuring plan through January 31, 2015, as we expect to complete restructuring activities in fiscal year 2015 for the FY 14 plan; we substantially completed restructuring activities in fiscal year 2014 for the FY13 plan. We incurred $(0.2) million of pre-tax restructuring costs for both three and six months ended January 31, 2015.

Taxes

For purposes of calculating non-GAAP net income and non-GAAP diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the non-GAAP adjustments described above as they have a significant impact on our income tax provision (benefit). In addition, from time-to-time, we recognize certain non-recurring tax adjustments.

During the three and six months ended January 31, 2014, we excluded from our non-GAAP results $8.8 million in non-recurring tax benefits primarily associated with our Canadian operations. These benefits were excluded from our non-GAAP results as the significant benefit recorded in the second quarter of fiscal year 2014 was non-recurring and management believes not helpful in evaluating short-term and longer-term trends in our operations. No similar benefit or adjustment was recognized during the three and six months ended January 31, 2015.

Summary

We exclude the above-described expenses, their related tax impact and other non-recurring tax benefits in evaluating short-term and long-term operating trends in our operations, and allocating resources to various initiatives and operational requirements. We believe that these non-GAAP financial adjustments are useful to investors because they allow investors to evaluate the effectiveness of the methodology and information used by management in its financial and operational decision-making.

These non-GAAP financial measures have not been prepared in accordance with GAAP, and should not be considered in isolation or as a substitute for financial information provided in accordance with GAAP. Further, these non-GAAP financial measures may not be computed in the same manner as similarly titled measures used by other companies. The following table reconciles the non-GAAP financial measures to their most directly comparable GAAP financial measures. 

               
NON-GAAP STATEMENTS OF OPERATIONS RECONCILIATION
               
(In thousands, except per share data) Three Months Ended   Six Months Ended
  January 31, 2015   January 31, 2014   January 31, 2015   January 31, 2014
               
GAAP Income From Operations $12,301   $13,084   $17,258   $7,719
Share-based compensation expense  2,424    3,104    5,015    5,839
Acquisition-related expenses  2,257    1,974    4,547    4,526
BK distributor matter inquiry related costs  376    580    1,146    911
Restructuring  (152)    335    (210)    296
Non-GAAP Income From Operations $17,206   $19,077   $27,756   $19,291
Percentage of Total Net Revenue 12.8%   13.5%   11.0%   7.7%
               
GAAP Other Expense, net ($169)   ($357)   ($51)   ($778)
Acquisition related loss  --     --     --     484
Non-GAAP Other Expense, net ($169)   ($357)   ($51)   ($294)
Percentage of Total Net Revenue -0.1%   -0.3%   0.0%   -0.1%
               
GAAP Net Income $9,830   $19,314   $13,484   $15,539
Share-based compensation expense  1,710    2,110    3,531    3,962
Acquisition related revenues, expenses and loss  1,903    1,594    3,841    4,116
BK distributor matter inquiry related costs  239    336    728    581
Restructuring  (96)    222    (133)    197
Tax benefit  --      (8,764)    --     (8,764)
Non-GAAP Net Income $13,586   $14,812   $21,451   $15,631
Percentage of Total Net Revenue 10.1%   10.5%   8.5%   6.2%
               
GAAP Diluted Net Income Per Share $0.78   $1.53   $1.07   $1.23
Effect of non-GAAP adjustments $0.30    (0.36)    0.63    -- 
Non-GAAP Diluted Net Income Per Share $1.08   $1.17   $1.70   $1.23

Michael Levitz Senior Vice President, Chief Financial Officer and Treasurer (978) 326-4058

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
De Beers Puts Namibia's 176-Carat Owishi on Display

Updated Category News Views 13

A 176-carat natural diamond can still make a room stop breathing, even in a trade battered by arguments over lab-grown supply, luxury spending, and what “rare” ought to mean anymore. De Beers Group, working with Grandview Klein Diamond, has unveiled Namibia’s Owishi natural diamond in Washington, DC. That is the hard fact on the table: a large Namibian stone, a U.S....

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Boat Market Forecast Puts Services in the Driver’s Seat

Updated Category News Views 51

A jet ski is not exactly a sober economic indicator, yet the water is telling a useful story. MarketsandMarkets projects the global recreational boat market will rise from $31.38 billion in 2026 to $48.06 billion in 2033, a 6.3% compound annual growth rate. That is respectable growth for a costly discretionary category that got knocked around by softer purchasing activity...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 131

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading

Top 5 Most Recently Viewed Articles

D.Law's New Office: A Major Step Forward in Growth

Updated Category News Views 158

D.Law Opens New Office in Glendale D.Law is excited to announce a significant milestone in its expansion with the launch of its new office at 450 N. Brand Blvd, Suite 840. This important development represents more than just a new location; it embodies the firm's dedication to growing its capabilities and providing better service to its clients. A New Beginning for D.Law...

Continue Reading
Innovative Hunting Shack Designed for Comfort and Covert Use

Updated Category News Views 155

Revolutionizing the Hunting Experience Hunting requires a blend of stealth, comfort, and practicality, all of which have inspired an exciting innovation: the specially designed hunting shack. An inventor focused on optimizing the hunting experience has created this remarkable mobile structure, ideal for outdoor enthusiasts seeking to enhance their hunting adventures. A...

Continue Reading
ALTA Honors Senate for Confirming Pulte as FHFA Director

Updated Category News Views 236

ALTA Celebrates Senate Confirmation of Bill Pulte The American Land Title Association (ALTA) has expressed its appreciation to the U.S. Senate following the confirmation of Bill Pulte as the new director of the Federal Housing Finance Agency (FHFA). This announcement marks a significant moment for both ALTA and the housing industry. Bill Pulte’s Role at FHFA Bill Pulte,...

Continue Reading
Celebrating Talar Guedikian's Achievement as Paralegal of the Year

Updated Category News Views 181

Talar Guedikian Named 2025 AAJ Paralegal of the Year The legal community is buzzing with excitement as Talar Guedikian, a dedicated Senior Litigation Paralegal, has been honored with the prestigious title of the 2025 AAJ Paralegal of the Year. This recognition, sponsored by Advocate Capital, showcases her exceptional capabilities and unwavering commitment to the legal...

Continue Reading
Bauer Hockey Welcomes Gillian Meek as New Executive Leader

Updated Category News Views 237

Bauer Hockey Appoints Gillian Meek as Executive Vice President Bauer Hockey, recognized globally as the leading manufacturer of hockey equipment and the premier brand within the sport, has made a significant executive change. The company has welcomed Gillian Meek as its new Executive Vice President and General Manager. This strategic move was announced recently, and it...

Continue Reading